Innovine Biomedicals Profile
Key Indicators
- Authorised Capital ₹ 7.00 Cr
as on 28-12-2024
- Paid Up Capital ₹ 5.85 Cr
as on 28-12-2024
- Company Age 6 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 11.00 Cr
as on 28-12-2024
- Satisfied Charges ₹ 8.00 Cr
as on 28-12-2024
- Revenue %
(FY 2022)
- Profit -117.22%
(FY 2022)
- Ebitda -366.20%
(FY 2022)
- Net Worth -232.64%
(FY 2022)
- Total Assets 13.14%
(FY 2022)
About Innovine Biomedicals
The Corporate was formerly known as Inovine Biomedicals Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.00 Cr and a paid-up capital of Rs 5.85 Cr.
The company currently has active open charges totaling ₹11.00 Cr. The company has closed loans amounting to ₹8.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Palakkadan Sudhakaran and Jishnu Sudhakaran serve as directors at the Company.
- CIN/LLPIN
U25209KL2018PTC053922
- Company No.
053922
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jul 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Thrissur, Kerala, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Innovine Biomedicals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jishnu Sudhakaran  | Managing Director | 04-Jul-2018 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Palakkadan Sudhakaran | Director | 04-Jul-2018 | Current |
Financial Performance of Innovine Biomedicals.
Innovine Biomedicals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 117.22% decrease in profit. The company's net worth observed a substantial decline by a decrease of 232.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Innovine Biomedicals?
Unlock access to Innovine Biomedicals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 26 Mar 2024 | ₹11.00 Cr | Open |
The South Indian Bank Limited Creation Date: 27 Jun 2022 | ₹8.00 Cr | Satisfied |
How Many Employees Work at Innovine Biomedicals?
Unlock and access historical data on people associated with Innovine Biomedicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Innovine Biomedicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Innovine Biomedicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
